FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, specifically to immunogenic peptides, and can be used to produce an antigen-presenting cell having activity on inducing a cytotoxic T-cell (CTL) targeted on a GPC3-expressing cancer cell.
EFFECT: invention enables efficient induction of specific CTL.
5 cl, 8 dwg, 2 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VACCINE COMPOSITION FOR MALIGNANT TUMOR | 2013 |
|
RU2721574C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| PEPTIDE, OBTAINED FROM MPHOSPH1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2731099C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
| PEPTIDE OBTAINED FROM DEPDC1 AND VACCINE CONTAINING IT | 2016 |
|
RU2765574C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
